Components prepared from whole blood* | |
Hepatitis B virus[1,2] | 1:1 million to 1:1.5 million |
Hepatitis C virus[1,2] | 1:2 million to 1:2.6 million |
HTLV[3,4] | 1:2.7 million |
HIV[1,2] | 1:1.6 million to 1:2.3 million |
Solvent/detergent-treated plasma products | |
Hepatitis C virus | Inactivated |
Hepatitis B virus | Inactivated |
HIV | Inactivated |
Hepatitis A virus | Not fully inactivated¶ |
Parvovirus B19 | Not fully inactivated¶ |
Hepatitis E virus | Not fully inactivated¶ |
Platelets | |
With automated bacterial culturing methods in place prior to 2019, septic transfusion reactions were estimated to occur at a rate of 1:50,000 to 1:80,000 transfused platelet apheresis units in the United States. This is thought to have been an underestimate since it relied on passive surveillance[5]. From 2019 onward, the risk is likely to have been lowered by enhanced bacterial safety methods. | |
CMV infection | |
The risk of CMV infection is rare in recipients who are at risk for severe morbidity from CMV due to conditions such as hematopoietic stem cell or solid organ transplantation and who receive CMV reduced-risk products. Two methods to supply CMV reduced-risk products that appear to have equal efficacy are CMV-seronegative cellular components (red blood cells, platelets) or leukoreduced components. |
CMV: cytomegalovirus; HIV: human immunodeficiency virus; HTLV: human T-lymphotropic virus.
* These estimates apply to red blood cells, platelets, and plasma, with the exception of HTLV, for which there is no risk from plasma.
¶ Plasma products are tested for parvovirus B19, hepatitis A virus, and hepatitis E virus nucleic acid before being used for further manufacturing into solvent/detergent-treated plasma. Transmission of these agents should not occur (or should be extraordinarily rare) under these conditions.